

05-05-05

IFW

Express Mail No.: EV 544892835 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Dingivan

Confirmation No.: 7146

Application No.: 10/091,313

Group Art Unit: 1616

Filed: March 4, 2002

Examiner: To Be Assigned

For: METHODS OF PREVENTING OR
TREATING INFLAMMATORY OR
AUTOIMMUNE DISORDERS BY
ADMINISTERING CD2 ANTAGONISTS
IN COMBINATION WITH OTHER
PROPHYLACTIC OR THERAPEUTIC
AGENTS

Attorney Docket No.: 10271-063-999

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. §1.56 AND §1.97

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure imposed by 37 C.F.R. §1.56 and §1.97 to inform the United States Patent and Trademark Office of all references coming to the attention of each individual associated with the filing or prosecution of the subject application, which are or may be material to the patentability of any claim of the application, Attorneys for Applicants hereby invite the Examiner's attention to references **B15 to B23**, and **C01 to C151** listed on the attached revised form PTO 1449 entitled "List of References Cited by Applicant." Copies of references **B15 to B23**, and **C01 to C151** are enclosed herewith.

While not to be construed as indicating that the Examiner should not fully consider the listed references, the Examiner's attention is particularly directed to the following references: **B16, B17, B18, B19, C23, C24, C32, C36, C39, C40, C45, C47, C48, C50, C59, C70, C74, C79, C84, C85, C87, C89, C90-C93, C95, C97, C100, C104, C116, C119, C122, C124, C126, C127, C128, C132, C144 and C146.**

Identification of the listed references is not meant to be construed as an admission of Applicants or Attorneys for Applicants that such references are available as "prior art" against the subject application.

Applicants respectfully request that the Examiner review the foregoing references and that the references be made of record in the file history of the application.

Pursuant to 37 C.F.R. § 1.97(b)(3), Applicants believe that no fee is due in connection with the filing of this Information Disclosure Statement. However, should the Patent Office determine otherwise, please charge the necessary fee to Jones Day Deposit Account No. 50-3013. A duplicate of this sheet is enclosed.

Respectfully submitted,


Date: May 3, 2005

Anthony M. Insogna 35,203
Anthony M. Insogna (Reg. No.)

JONES DAY
222 East 41st Street
New York, New York 10017-6702
(212) 326-3939

Enclosures

By: Jennifer J. Chioda
Reg No. 46,617

| | | | | |
|---|---|---------------|-----------------------------------|-------------------------------|
|  | LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary) | | ATTY. DOCKET NO. 10271-063-999 | APPLICATION NO. 10/091,313 |
| | APPLICANT Dingivan | | | |
| | FILING DATE March 4, 2002 | GROUP 1616 | | |

U.S. PATENT DOCUMENTS

| *EXAMINER INITIAL | DOCUMENT NUMBER | DATE | NAME | CLASS | SUBCLASS | FILING DATE IF APPROPRIATE |
|----------------------|-----------------|------|------|-------|----------|-------------------------------|
| | | | | | | |
| | | | | | | |

FOREIGN PATENT DOCUMENTS

| | DOCUMENT NUMBER | DATE | COUNTRY | CLASS | SUBCLASS | TRANSLATION | |
|--|-----------------|-------------|----------|-------|----------|-------------|----|
| | | | | | | YES | NO |
| | B15 | WO 96/04388 | 2/15/96 | PCT | | | |
| | B16 | WO 94/20619 | 9/15/94 | PCT | | | |
| | B17 | WO 93/06866 | 4/15/93 | PCT | | | |
| | B18 | WO 93/06852 | 4/15/93 | PCT | | | |
| | B19 | WO 92/16622 | 10/1/92 | PCT | | | |
| | B20 | WO 89/05155 | 6/15/89 | PCT | | | |
| | B21 | EP 555880 | 8/18/93 | EP | | | |
| | B22 | EP 394827 | 10/31/90 | EP | | | |
| | B23 | EP 367166 | 5/9/90 | EP | | | |

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

| | |
|-----|--|
| C01 | Dialog Accession No.: 469651, CEABA Accession No.: 30-12-019253. Medimmune Biotransplant Trial Results. Biotechnology Newswatch, 19 July 1999 |
| C02 | GenBank AF018081 Human type XVIII collagen (COL18A1) m RNA, alternatively spliced, long form, complete cds |
| C03 | GenBank AF018082 Human type XVIII collagen (COL18A1) m RNA, alternatively spliced, short form, complete cds |
| C04 | GenBank AH002740 human T-cell surface antigen T11 (CD2) gene, exon 1, clone PB2 |
| C05 | GenBank CAA29622 |
| C06 | GenBank E12817 cDNA encoding human LFA-3 |
| C07 | GenBank M16445 human surface antigen CD2 mRNA, complete cds |
| C08 | GenBank NM_000301 human plasminogen (PLG), mRNA |
| C09 | GenBank NM_000948 human prolactin (PRL), mRNA |
| C10 | GenBank X06143 murine mRNA for T11 protein |
| C11 | Abrams et al., 2000, "Blockade of T lymphocyte costimulation with cytotoxic T lymphocyte-associated antigen 4-immunoglobulin (CTLA4Ig) reverses the cellular pathology of psoriatic plaques, including the activation of keratinocytes, dendritic cells, and endothelial cells," J. Exp. Med. 192(5):681-694 |
| C12 | Adkins et al., 2000, "A phase I placebo-controlled, randomized, dose-escalation safety study of MEDI-507, a humanized anti-DC2 monoclonal antibody, in the initial treatment of at least grade II acute graft-versus host disease," Blood 96:476A |
| C13 | Ames et al., 1995, "Conversion of murine Fabs isolated from a combinatorial phage display library to full length immunoglobulins," J. Immunol. Methods 184:177-186 |
| C14 | Anasetti et al., 2000, "Anti-CD3 F(AB') ₂ prevents Graft-Versus-Host Disease by selectively depleting donor T cells activated by recipient alloantigens," Itinerary for the American Society of Hematology 42 nd Annual Meeting, 12/4/00 |
| C15 | Arnon et al., 1985, "Monoclonal antibodies for immunotargeting of drugs in cancer therapy," in: <i>Monoclonal Antibodies and Cancer Therapy</i> , Reisfeld et al., eds., Alan R. Liss, Inc., pp. 243-256 |
| C16 | Asadullah et al., 1999, "Interleukin-10 in Cutaneous Disorders: Implications for Its Pathophysiological Importance and Therapeutic Use," Arch. Dermatol. Res. 291(12):628-36 |
| C17 | Ashcroft et al., 2000, "Therapeutic strategies for psoriasis," J. Clin. Pharm. Ther. 25:1-10 |
| C18 | Ashkenazi et al., 1991, "Protection against endotoxic shock by a tumor necrosis factor receptor immunoadhesin," Proc. Natl. Acad. Sci. USA 88:10535-10539 |
| C19 | Ausubel et al., eds., 1999, <i>Current Protocols in Molecular Biology</i> , John Wiley & Sons, NY, pp. 2.10.3 and 6.3.1 - 6.3.6 |
| C20 | Baldwin et al., eds., 1985, "Analysis, results and future prospective of the therapeutic use of radiolabeled antibody in cancer therapy," in: <i>Monoclonal Antibodies for Cancer Detection and Therapy</i> , Academic Press, pp. 303-316 |

| | |
|-----|--|
| C21 | Bathon et al., 2000, "A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis," N. Eng. J. Med. 343:1586-1602 |
| C22 | Bauer et al., 1999, "Population pharmacokinetics and pharmacodynamics of the anti-CD11a antibody hu1124 in human subjects with psoriasis," J. Pharmacokinetics Biopharmaceutics 27:397-420 |
| C23 | Besse et al., 1997, "Prevention of Rejection with BTI-322 After Renal Transplantation (Results at 9 Months)" Transplantation Proc. 29:2425-2426 |
| C24 | Branco et al., 1999, "Selective deletion of antigen-specific, activated T cells by a humanized MAB to CD2 (MEDI-507) is mediated by NK cells," Transplantation 68:1588-1596 |
| C25 | Buchwald et al., 1980, "Long-term, continuous intravenous heparin administration by an implantable infusion pump in ambulatory patients with recurrent venous thrombosis," Surgery 88:507-516 |
| C26 | Camisa, 2000, "Psoriasis: A Clinical Update on Diagnosis and New Therapies," Cleve Clin. J. Med. 67(2):105-106 |
| C27 | Cao et al., 1996, "Krigle domains of human angiostatin. Characterization of the anti-proliferative activity on endothelial cells," J. Biol. Chem. 271:29461-29467 |
| C28 | Carpenter et al., 2000, "Humanized non-FCR-binding anti-CD3 antibody as therapy for glucocorticoid refractory acute GVHD," Itinerary for the American Society of Hematology 42 nd Annual Meeting, 12/4/00, Location 305 |
| C29 | Carrell, 1999, "How serpins are shaping up," Science 285:1861-1862 |
| C30 | Cathcart et al., 1986, "Experimental arthritis in a nonhuman primate. I. Induction by bovine type II collagen," Lab. Invest. 54:26-31 |
| C31 | Chiorazzi, 1986, "Human monoclonal antibodies as probes to study autoimmune and allergic disorders," Biotechnology 4:210-218 |
| C32 | Chisholm et al., 1994, "The effects of an immunomodulatory LFA3-IgG ₁ fusion protein on nonhuman primates," Therapeutic Immunity 1:205-216 |
| C33 | Chong, 1996, "Receptors that turn on and turn off natural killer cells," J Heart Lung Transplant. 15(7):675-683 |
| C34 | Cleek et al., 1997, Proc. Intl. Symp. Control. Rel. Bioact. Mater. 24:853-854 |
| C35 | Cohn et al., 1997, "Induction of airway mucus production By T helper 2 (Th2) cells: a critical role for interleukin 4 in cell recruitment but not mucus production," J. Exp. Med. 186:1737-1747 |
| C36 | Couriel et al., 2000, "Infliximab for the treatment of Graft-Versus-Host disease in allogeneic transplant recipients: an update," Itinerary for the American Society of Hematology 42 nd Annual Meeting, 12/4/00, Poster Board Number 775 |
| C37 | Courtenay et al., 1980, "Immunisation against heterologous type II collagen induces arthritis in mice," Nature 283:666-668 |
| C38 | Crowley et al., 1993, "Prevention of metastasis by inhibition of the urokinase receptor," Proc. Natl. Acad. Sci. USA 90:5021-5025 |
| C39 | Davis et al., 1996, "The Structure and Ligand Interactions of CD2: Implications for T-Cell Function," Immunology Today 17(4):177-187 |
| C40 | Dehoux et al., 2000, "Effects on human and nonhuman primate immune response of a new rat anti-CD2 monoclonal antibody," Transplantation 69:2622-2633 |
| C41 | Devrimci-Ozguven et al., 2000, "The depression, anxiety, life satisfaction and affective expression levels in psoriasis patients," J. Eur. Acad. Dermatol. Venereol. 14:267-271 |
| C42 | Diasio et al., 1996, "Immunomodulators: Immunosuppressive agents and immunostimulants," in: The Pharmacological Basis of Therapeutics, McGraw-Hill, New York, Ch. 52, pp. 1291-1306 |
| C43 | DiSepio et al., 2000, "New Drugs in the Treatment of Psoriasis," Expert Opin Investig Drugs 9(1):79-93 |
| C44 | Drew, 2000, "Psoriasis," Primary Care 27:385-406 |
| C45 | Dumont et al., 1998, "Potent apoptotic signaling and subsequent unresponsiveness induced by a single CD2 mAb (BTI-322) in activated human peripheral T Cells," J. Immunol. 3797-3804 |
| C46 | Durie et al., 1994, "The role of CD40 in the regulation of humoral and cell-mediated immunity," Immunol. Today 15:406-411 |
| C47 | Ellis, 1999, "Quality of Life (QOL) of Amevive™ (LFA3TIP) in patients with chronic plaque psoriasis," Amevive Breakfast Meeting, 12/3/99 and abstract from Br. J. Dermatol. 141:990 Abstract 82 |
| C48 | Ellis et al., "Quality of Life (QOL) in Patients with Chronic Psoriasis Treated with AMEVIVE (LFA3TIP)," Poster Presentation |
| C49 | Feldmann, M. 'Cytokine Inhibitors: Biologics'. In: Inflammation: Basic Principles and Clinical Correlates. 3 rd Edition, Ed. Gillian and Synderman. Lippincott Williams & Wilkins (Philadelphia) 1999, pages 1207-1212 |
| C50 | Ferrant et al., 1997, "LO-CD2a/BTI322 for Steroid Resistant Graft-Versus-Host Disease," BTI Ref 1979, (Something) Transplant 19(Supp. 1): S181 Abstract P721 |
| C51 | Flanders et al., 1999, "Prevention of type I diabetes from laboratory to public health," Autoimmun. 29:235-246 |
| C52 | Foster, 1999, "Relevance of systemic lupus erythematosus nephritis animal models to human disease," Semin. Nephrol. 19:12-24 |
| C53 | Fredriksson and Pettersson, 1978, "Severe psoriasis--oral therapy with a new retinoid," Dermatologica 157:238-244 |
| C54 | Goodson et al., 1994, "High-affinity urokinase receptor antagonists identified with bacteriophage peptide display," Proc. Natl. Acad. Sci. USA 91:7129-7133 |
| C55 | Goodson, 1984, "Effects of administration of a single dose of a humanized monoclonal antibody to CD11a on the immunobiology and clinical activity of psoriasis," in: <i>Medical Applications of Controlled Release</i> , vol. 2, pp. 115-138 |
| C56 | Gottlieb et al., 2000, "Anti-CD4 monoclonal antibody treatment of moderate to severe psoriasis vulgaris: results of a pilot, multicenter, multiple-dose, placebo-controlled study," J. Am. Acad. Dermatol. 43:595-604 |

| | |
|-----|--|
| C57 | Gottlieb et al., 2000, "Effects of administration of a single dose of a humanized monoclonal antibody to CD11a on the immunobiology and clinical activity of psoriasis," J. Am. Acad. Dermatol. 42:428-435 |
| C58 | Greaves and Weinstein, 1995, "Treatment of psoriasis," N. Eng. J. Med. 332:581-588 |
| C59 | Griffiths, 1999, "T cell targeting for psoriasis," Amevive Breakfast Meeting, 12/3/99 |
| C60 | Guzzo et al., 1996, "Dermatological pharmacology," in: The Pharmacological Basis of Therapeutics, McGraw-Hill, New York, Hardman et al., eds., Ch. 64, pp. 1593-1613 |
| C61 | Hansra et al., 2000, "Carrageenan-induced arthritis in the rat," Inflammation 24:141-155 |
| C62 | Harari et al., 2000, "Clinical evaluation of a more rapid and sensitive Psoriasis Assessment Severity Score (PASS), and its comparison with the classic method of Psoriasis Area and Severity Index (PASI), before and after climatotherapy at the Dead-Sea," Int. J. Dermatol. 39:913-918 |
| C63 | Hellstrom et al., 1987, "Antibodies for drug delivery," in: <i>Controlled Drug Delivery</i> 2 nd ed., Robinson et al., eds., Marcel Dekker, Inc. pp. 623-653 |
| C64 | Heslop et al., 2000, "ABX-CBL monoclonal antibody in patients with steroid resistant graft versus host disease," Itinerary for the American Society of Hematology 42 nd Annual Meeting, 12/4/00, Abstract 305 |
| C65 | Holmdahl, 1999, "Autoimmunity: Another pathway towards arthritis," Curr. Biol. 9:R528-530 |
| C66 | Howard et al., 1989, "Intracerebral drug delivery in rats with lesion-induced memory deficits," J. Neurosurg. 71:105-112 |
| C67 | Husted et al., 1995, "A modified version of the Health Assessment Questionnaire (HAQ) for psoriatic arthritis," Clin. Exp. Rheumatol. 13:439-443 |
| C68 | Jemec and Wulf, 1997, "The applicability of clinical scoring systems: SCORAD and PASI in psoriasis and atopic dermatitis," Acta Derm. Venereol. 77:392-393 |
| C69 | Jooss et al., 1996, "Cyclophosphamide diminishes inflammation and prolongs transgene expression following delivery of adenoviral vectors to mouse liver and lung," Hum. Gene Ther. 7:1555-1566 |
| C70 | Kaplon et al., 1996, "Short Course Single Agent Therapy with an LFA-3-IgG1 Fusion Protein Prolongs Primate Cardiac Allograft Survival," Transplantation 61(3):356-363 |
| C71 | Karasek, 1999, "Progress in our understanding of the biology of psoriasis," Cutis 64:319-322 |
| C72 | Kim and Berstad, 1992, "Experimental colitis in animal models," Scand. J. Gastroenterol. 27:529-537 |
| C73 | Kohn et al., 1990, "A second tumor necrosis factor receptor gene product can shed a naturally occurring tumor necrosis factor inhibitor," Proc. Natl. Acad. Sci. USA 87:8331-8335 |
| C74 | Kozarsky et al., 1993, "An anti-CD2 monoclonal antibody that both inhibits and stimulates T cell activation recognizes a subregion of CD2 distinct from known ligand-binding sites," Cell Immunol. 150:235-246 |
| C75 | Krieger et al., 1997, "The use of CD4 and CD8 knockout mice to study the role of T-cell subsets in allotransplant rejection," J. Heart Lung Transplant. 16:263-267 |
| C76 | Krogh et al., 1999, "Models to study the pathogenesis of thyroid autoimmunity," Biochimie 81:511-515 |
| C77 | Krueger et al., 2000, "Anti-CD11a Treatment for Psoriasis Concurrently Increases Circulating T-cells and Decreases Plaque T-cells, Consistent with Inhibition of Cutaneous T-cell Trafficking," J. Invest. Dermatol. 115(2):333 |
| C78 | Krueger et al., 2000, "Successful in vivo Blockade of CD25 (High-Affinity Interleukin 2 Receptor) on T Cells by Administration of Humanized Anti-Tac Antibody to Patients with Psoriasis," J. Am. Acad. Dermatol. 43(3):448-458 |
| C79 | Krueger, 1999, "Efficacy and safety results of a phase II trial with LFA3TIP in patients with chronic plaque psoriasis," Amevive Breakfast Meeting 12/3/99 |
| C80 | Krueger, 1999, "Phase II trial results of Amevive™ (LFA3TIP) in patients with chronic plaque psoriasis," Br. J. Dermatol. 141:979-980, Abstract 39 |
| C81 | Kutemeier et al., 1994, "Assembly of humanized antibody genes from synthetic oligonucleotides using a single-round PCR," Biotechniques 17:242-246 |
| C82 | Lafaille et al., 1994, "High incidence of spontaneous autoimmune encephalomyelitis in immunodeficient anti-myelin basic protein T cell receptor transgenic mice," Cell 78(3):399-408 |
| C83 | Langer and Peppas, 1983, J. Macromol. Sci. Rev. Macromol. Chem. 23:61 |
| C84 | Latinne et al., 1997, "BTI-322, An Anti-Human CD2 MAB, Elicits Specific Depletion of T Cells Activated by Anti-TCR VbMAB," Abstract form for: The American Society of Transplant Physicians, 15 th Annual Scientific Meeting May 10-14 |
| C85 | Latinne et al., 1996, "An anti-CD2 mAb induces immunosuppression and hyporesponsiveness of CD2+ human T cells in vitro," Int. Immunol. 8:1113-1119 |
| C86 | Lebwohl, 2000, "Advances in psoriasis therapy," Dermatol. Clin. 18:13-19 |
| C87 | Lerut et al., "The Use of Tacrolimus (TAC) and Anti-CD2 Antibody Lo-CD2a (BTI-322) in Adult Liver Transplantation (LT): Preliminary Results of a Prospective Randomized Study," Abstract 102 |
| C88 | Levy et al., 1985, "Inhibition of calcification of bioprosthetic heart valves by local controlled-release diphosphonate," Science 228:190-192 |
| C89 | Li et al., 1995, "CD2 Antigen: Signaling Features and Strategies to Inhibit CD2 Antigen-Derived Signals," in Recent Developments in Transplantation Medicine V.2, Ch. 7, Salomon and Sollinger, eds., pp. 97-121 |
| C90 | Magilavy et al., "Immunopharmacologic effects of AMEVIVE™ (LFA3TIP) in chronic plaque psoriasis: Selectivity for peripheral memory effector (CD45RO+) over naïve (CD45RA+) T cells," Poster presentation and abstract from Br. J. Dermatol. 141:990, Abstract 81 |
| C91 | Magilavy et al., 2000, "The Response of Plaque Psoriasis to Amevive™ (LFA3TIP) and the Selective Suppression of Memory/Effector T Cells (CD45RO+) Verses Naïve T Cells (CD45RA+) Is Serum Levels of LFA3TIP," J. Invest. |

| | |
|------|--|
| | Dermatol. 114(4):776 Abstract 148 |
| C92 | Magilavy et al., 1999, "Pharmacodynamic effects of Amevive™ (LFA3TIP), a LFA-3/igg Fc fusion protein in chronic plaque psoriasis: selectivity for peripheral memory-effector (CD45RO+) over naïve (CD45RA+) T cells," Amevive Breakfast Meeting, 12/3/99 |
| C93 | Majeau et al., 1994, "Mechanism of Lymphocyte Function-Associated Molecule 3-Ig Fusion Proteins Inhibition of T Cell Responses," J. Immunol. 152(6):2753-67 |
| C94 | Margolis et al., 2000, "Pentostatin: A novel treatment for steroid refractory acute GHVD," Itinerary for the American Society of Hematology 42 nd Annual Meeting, 12/4/00, Poster Board Number 774 |
| C95 | Meier et al., 1995, "Immunomodulation by LFA3TIP, an LFA-3/IgG1 Fusion Protein: Cell Line Dependent Glycosylation Effects on Pharmacokinetics and Pharmacodynamic Markers," Ther. Immunol. 2(3):159-171 |
| C96 | Merck Manual of Diagnosis and Therapy, Seventeenth Edition. Ed. Beers and Berkow. Merck Research Laboratories (Whitehouse Station, NJ), 1999, pages 416-423 |
| C97 | Miller et al., 1993, "Specific interaction of lymphocyte function-associated antigen 3 with CD2 can inhibit T cell responses," J. Exp. Med. 178:211-222 |
| C98 | Min et al., 1996, "Urokinase receptor antagonists inhibit angiogenesis and primary tumor growth in syngeneic mice," Cancer Res. 56:2428-2433 |
| C99 | Mollee et al., 2000, "Combination therapy with antithymocyte globulin (ATG) and tacrolimus for patients with steroid refractory GHVD," Itinerary for the American Society of Hematology 42 nd Annual Meeting, 12/4/00 |
| C100 | Mollereau et al., 1999, "Effects of Anti-CD2 Monoclonal Antibody: CD2- and CD95-Mediated Apoptosis of Human Peripheral T Cells," Transplantation Proc. 31:1245 |
| C101 | Mourad et al., 1997, "BTI-322 for Acute Rejection After Renal Transplantation," Transplantation Proc. 29:2353 |
| C102 | Nevitt and Hutchinson, 1996, "Psoriasis in the community: prevalence, severity and patients' beliefs and attitudes towards the disease," Brit. J. Dermatol. 135:533-537 |
| C103 | Ning et al., 1996, "Intratumoral radioimmunotherapy of a human colon cancer xenograft using a sustained-release gel," Radiother. Oncol. 39:179-189 |
| C104 | Nizet et al., 2000, "The experimental (in vitro) and clinical (in vivo) immunosuppressive effects of a rat IgG2b anti-human CD2 mAb, LO-CD2a/BTI-322," Transplantation 69(7):1420-1428 |
| C105 | Oi et al., 1986, BioTechniques 4:214 |
| C106 | Order, 1985, "Analysis, results and future prospective of the therapeutic use of radiolabeled antibody in cancer therapy," in: <i>Monoclonal Antibodies for Cancer Detection and Therapy</i> , Baldwin et al., eds., Academic Press, pp. 303-316 |
| C107 | O'Reilly et al., 1999, "Antiangiogenic activity of the cleaved conformation of the serpin antithrombin," Science 285:1926-1928 |
| C108 | Ortonne, 1999, "Recent Developments in the Understanding of the Pathogenesis of Psoriasis," Br. J. Dermatol. 140 Suppl 54:1-7 |
| C109 | Oswald et al., 1992, "Interleukin 10 inhibits macrophage microbicidal activity by blocking the endogenous production of tumor necrosis factor alpha required as a costimulatory factor for interferon gamma-induced activation," Proc. Natl. Acad. Sci. USA 89:8676-8680 |
| C110 | Papp et al., 1999, "The treatment of moderate to severe psoriasis with hu1124: a new monoclonal antibody," Br. J. Dermatol. 141:980, Abstract 40 |
| C111 | Pasquini et al., 2000, "Basiliximab (BaMab) - a selective interleukin-2 receptor (IL-2R) antagonist - as therapy for refractory acute Graft Versus Host Disease (a-GHVD) following bone marrow transplantation (BMT)," Itinerary for the American Society of Hematology 42 nd Annual Meeting, 12/4/00, Poster Board No. 762 |
| C112 | Paul, ed., 1989, <i>Fundamental Immunology</i> 2 nd Ed., Raven Press, NY, pp. 332-336 |
| C113 | Peters et al., 2000, "Pathophysiology and treatment of psoriasis," Am. J. Health Sys. Pharm. 57:645-659 |
| C114 | Phillips et al., 1993, "Infectious agents in chronic rheumatic diseases," in: <i>Arthritis and Allied Conditions: A Textbook of Rheumatology</i> , Lee & Febiger, eds., Chapter 30 |
| C115 | Potter et al., 2000, "Campath 1 H "In the Bag" is an effective method of GHVD prevention in allogeneic stem cell transplantation," Itinerary for the American Society of Hematology 42 nd Annual Meeting, 12/4/00, Location 305 |
| C116 | Przepiorika et al., "Pharmacokinetics and Safety of BTI-322, a Rat Anti-CD2 Monoclonal Antibody for Treatment of Steroid-Resistant Acute Graft-Versus-Host Disease," BTI Ref 3623 |
| C117 | Przepiorika et al., 1998, "A Phase II Study of BTI-322, a Monoclonal Anti-CD2 Antibody, for Treatment of Steroid-Resistant Acute Graft-Versus-Host Disease," Blood 92(11):4066-4071 |
| C118 | Rabinowitz et al., 1995, "In vitro activation leads to the binding of T-cell markers to the surface of B-lymphocytes," Clin. Immunol. Immunopathol. 76:148-154 |
| C119 | Ratanathathorn et al., 1999, "Pharmacokinetics and Safety of Medi-507, a Humanized Anti-CD2 Monoclonal Antibody in Severe Steroid-Resistant Graft-Versus-Host Disease," International Society for Experimental Hematology, Abstract 119 |
| C120 | Robert et al., 1999, "Inflammatory skin diseases, T cells, and immune surveillance," New England J of Med. 341(24):1817-1828 |
| C121 | Roenigk et al., 1988, "Methotrexate in psoriasis: revised guidelines," J. Am. Acad. Dermatol. 19(1 pt. 1):145-156 |
| C122 | Rouleau et al., 1997, "CD2 Induced Apoptosis of Peripheral T Cells," Transplantation Proc. 29:2377-2378 |
| C123 | Saudek et al., 1989, "A preliminary trial of the programmable implantable medication system for insulin delivery," N. Engl. J. Med. 321:574-579 |
| C124 | Schad et al., 1996, "An Anti-CD2 Monoclonal Antibody That Elicits Alloantigen-Specific Hyporesponsiveness," |

| | |
|--|--|
| | Transplantation Proceedings 28(4):2051-2053 |
| C125 | Seckinger et al., 1990, "Characterization of a tumor necrosis factor alpha (TNF-alpha) inhibitor: evidence of immunological cross-reactivity with the TNF receptor," Proc. Natl. Acad. Sci. USA 87:5188-5192 |
| C126 | Spitzer et al., 2000, "Haploidentical donor bone marrow transplantation for advanced hematologic malignancy following non-myeloablative preparative therapy: role of in vivo T cell depletion with anti-thymocyte globulin or anti-CD2 monoclonal antibody therapy," Blood 96:841A |
| C127 | Squifflet et al., 1997, "BTI-322 for Induction Therap after Renal Transplantation: A Randomized Study," Transplant Proc. 29(1-2):317-319 |
| C128 | Squifflet et al., 1997, "A Randomized Study of BTI-322 for the Prevention of Renal Allograft Rejection: One Year Follow Up," Abstract form for: The American Society of Transplant Physicians, 15 th Annual Scientific Meeting May 10-14 |
| C129 | Stern, 1995, "Epidemiology of psoriasis," Dermatol. Clin. 13:717-722 |
| C130 | Stern and Laird, 1994, "The carcinogenic risk of treatments for severe psoriasis. Photochemotherapy Follow-up Study," Cancer 73:2759-2764 |
| C131 | Strober, 1985, "Animal models of inflammatory bowel disease--an overview," Dig. Dis. Sci. 30(12 suppl.):3S-10S |
| C132 | Sultan et al., 1997, "Blockade of CD2-LFA-3 Interactions Protects Human Skin ALlografts in Immunodeficient Mouse/Human Chimeras," Nature Biotechnology 15:759-762 |
| C133 | Takahashi et al., 1994, "Human Fas ligand: gene structure, chromosomal location and species specificity," Int. Immunol. 6:1567-1574 |
| C134 | Thorbecke et al., 1992, "Involvement of endogenous tumor necrosis factor alpha and transforming growth factor beta during induction of collagen type II arthritis in mice," Proc. Natl. Acad. Sci. USA 89:7375-7379 |
| C135 | Thorpe, 1985, "Antibody carriers of cytotoxic agents in cancer therapy: a review," in: <i>Monoclonal Antibodies '84: Biological and Clinical Applications</i> , Pinchera et al., eds., pp. 475-506 |
| C136 | Thorpe and Ross, 1982, "The preparation and cytotoxic properties of antibody-toxin conjugates," Immunol. Rev. 62:119-158 |
| C137 | Trautnecker et al., 1988, "Soluble CD4 molecules neutralize human immunodeficiency virus type 1," Nature 331:84-86 |
| C138 | Trentham et al., 1977, "Autoimmunity to type II collagen an experimental model of arthritis," J. Exp. Med. 146(3):857-868 |
| C139 | Tutt et al., 1991, "Trispecific F(ab') ₃ derivatives that use cooperative signaling via the TCR/CD3 complex and CD2 to activate and redirect resting cytotoxic T cells," J. Immunol. 147:60-69 |
| C140 | Vie et al., 1992, "Human fusion proteins between interleukin 2 and IgM heavy chain are cytotoxic for cells expressing the interleukin 2 receptor," Proc. Natl. Acad. Sci. USA 89:11337-11347 |
| C141 | Williams et al., 1994, "Synergy between anti-CD4 and anti-tumor necrosis factor in the amelioration of established collagen-induced arthritis," Proc. Natl. Acad. Sci. USA 91:2762-2766 |
| C142 | Winter et al., 1962, "Carrageenan-induced edema in hind paw of the rat as an assay for anti-inflammatory drugs," Proc. Soc. Exp. Biol. Med. 111:544-547 |
| C143 | Woodward et al., 1996, "Blockade of multiple costimulatory receptors induces hyporesponsiveness," Transplantation 62(7):1011-1018 |
| C144 | Wu et al., 1998, "Stepwise in vitro affinity maturation of Vitaxin, an alphav beta3-specific humanized mAb," Proc. Natl. Acad. Sci. USA 95:6037-6042 |
| C145 | Wu and Wu, 1987, "Receptor-mediated in vitro gene transformation by a soluble DNA carrier system," J. Biol. Chem. 262:4429-4432 |
| C146 | Xu et al., 2000, "Inhibition of Human Anti-Pig T Cell Response by Anti-CD2, Anti-CD40L, and CTLA4-Ig: A Comparative Study," Transplantation Proc. 32:926 |
| C147 | Yamamoto et al., 1998, "The integrin ligand echistatin prevents bone loss in ovariectomized mice and rats," Endocrinol. 139:1411-1419 |
| C148 | Yokota et al., 1986, "Isolation and characterization of a human interleukin cDNA clone, homologous to mouse B-cell stimulatory factor 1, that expresses B-cell- and T-cell-stimulating activities," Proc. Natl. Acad. Sci. USA 83:5894-5898 |
| C149 | Yoshitake et al., 1999, "Osteopontin-deficient mice are resistant to ovariectomy-induced bone resorption," Proc. Natl. Acad. Sci. USA 96:8156-8160 |
| C150 | Zamvil and Steinman, 1990, "The T lymphocyte in experimental allergic encephalomyelitis," Annu. Rev. Immunol. 8:579-621 |
| C151 | Zheng et al., 1995, "Administration of noncytolytic IL-10/Fc in murine models of lipopolysaccharide-induced septic shock and allogeneic islet transplantation," J. Immunol. 154:5590-5600 |
| EXAMINER | |
| DATE CONSIDERED | |
| <p>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p> | |